Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 19/20 | 0.63 |
| ▸ | PDE4A | P27815 | 18/20 | 0.63 |
| ▸ | PDE4B | Q07343 | 18/20 | 0.63 |
| ▸ | PDE4C | Q08493 | 18/20 | 0.63 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.56 |
| ▸ | GFER | P55789 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6963861 | 0.81 | PDE4D (0.75) | PDE4DPDE4APDE4BPDE4CPDE11A | |
| SCHEMBL8344275 | 0.79 | PDE4D (0.63) | PDE4DPDE4APDE4BPDE4CPDE11A | |
| SCHEMBL6950190 | 0.78 | PDE4D (0.67) | PDE4DPDE4APDE4BPDE4CPDE11A | |
| SCHEMBL5723087 | 0.78 | PDE4D (0.68) | PDE4DPDE4APDE4BPDE4CPDE11A | |
| SCHEMBL8269400 | 0.78 | PDE4D (0.64) | PDE4DPDE4APDE4BPDE4CPDE11A | |
| SCHEMBL3471216 | 0.78 | PDE4D (0.61) | PDE4DPDE4APDE4BPDE4CPDE11A | |
| SCHEMBL8633792 | 0.77 | PDE4D (0.69) | PDE4DPDE4APDE4BPDE4CPDE11A | |
| SCHEMBL155477 | 0.77 | PDE4D (1.00) | PDE4DPDE4APDE4BPDE4CPDE11A | |
| SCHEMBL6833145 | 0.77 | PDE4D (0.65) | PDE4DPDE4APDE4BPDE4CPDE11A | |
| SCHEMBL5798456 | 0.76 | PDE4D (0.63) | PDE4DPDE4APDE4BPDE4CPDE11A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0944616-B1 | BICYCLIC ARYL CARBOXAMIDES AND THEIR THERAPEUTIC USE | DARWIN DISCOVERY LTD (GB) | 2003-06-04 | — | — | EP | claimed |
| US-6353010-B1 | ENZYME INHIBITORS TUMOR NECROSIS FACTOR AND PHOSPHODIESTERASE FOR ANTIINFLAMMATORY AGENTS | DARWIN DISCOVERY, LTD. (GB) | 2002-03-05 | — | — | US | claimed |
| EP-0944616-A1 | BICYCLIC ARYL CARBOXAMIDES AND THEIR THERAPEUTIC USE | Darwin Discovery Limited (GB) | 1999-09-29 | — | — | EP | claimed |
| WO-1998022460-A1 | BICYCLIC ARYL CARBOXAMIDES AND THEIR THERAPEUTIC USE | DARWIN DISCOVERY LIMITED (GB) | 1998-05-28 | — | — | WO | claimed |
| EP-0944616-B1 | BICYCLIC ARYL CARBOXAMIDES AND THEIR THERAPEUTIC USE | DARWIN DISCOVERY LTD (GB) | 2003-06-04 | — | — | EP | disclosed |
| US-20020094987-A1 | Bicyclic aryl carboxamides and their therapeutic use | DYKE HAZEL JOAN (GB) | 2002-07-18 | — | — | US | disclosed |
| US-6353010-B1 | ENZYME INHIBITORS TUMOR NECROSIS FACTOR AND PHOSPHODIESTERASE FOR ANTIINFLAMMATORY AGENTS | DARWIN DISCOVERY, LTD. (GB) | 2002-03-05 | — | — | US | disclosed |
| EP-0944616-A1 | BICYCLIC ARYL CARBOXAMIDES AND THEIR THERAPEUTIC USE | Darwin Discovery Limited (GB) | 1999-09-29 | — | — | EP | disclosed |
| WO-1998022460-A1 | BICYCLIC ARYL CARBOXAMIDES AND THEIR THERAPEUTIC USE | DARWIN DISCOVERY LIMITED (GB) | 1998-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020094987-A1 | Bicyclic aryl carboxamides and their therapeutic use | PDE3B, PDE3A, PDE2A | PDE4D 25/4885PDE4A 9/4885PDE4B 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.